TABLE 1.
Baseline data in the testing group
| Variables | Hypertension with ischemic stroke | Hypertension without ischemic stroke | χ 2/t | p |
|---|---|---|---|---|
| Number of patients | 92 | 114 | ||
| Age, (mean ±SD) | 53.8 ± 6.2 | 54.0 ± 7.0 | −0.214 | 0.830 |
| Male (%) | 48 (52.2) | 54 (47.4) | 0.470 | 0.493 |
| Body mass index (mean ±SD, kg/m2) | 23.5 ± 1.7 | 23.7 ± 1.8 | −0.813 | 0.417 |
| Diabetes (%) | 13 (14.1) | 15 (13.2) | 0.041 | 0.840 |
| Smoking (%) | 6 (6.5) | 9 (7.9) | 0.142 | 0.706 |
| Drinking (%) | 25 (27.2) | 29 (25.4) | 0.079 | 0.778 |
| CTLA−4 concentrations (mean ±SD, ng/mL) | 5.3 ± 1.6 | 4.6 ± 1.5 | 3.232 | 0.001 |
| Lp‐PLA2 concentrations (mean ±SD, ng/mL) | 27.5 ± 7.3 | 17.8 ± 6.9 | 9.774 | <0.001 |
| HCY concentrations (mean ±SD, nmol/L) | 61.1 ± 8.8 | 55.7 ± 10.2 | 4.013 | <0.001 |
| MIP concentrations (mean ±SD, pg/mL) | 102.9 ± 21.5 | 97.5 ± 22.3 | 1.921 | 0.093 |
| IMA concentrations (mean ±SD, pg/mL) | 1.9 ± 0.6 | 1.2 ± 0.5 | 9.133 | <0.001 |
| GFAP concentrations (mean ±SD, mg/L) | 105.5 ± 24.1 | 93.7 ± 26.7 | 3.292 | 0.001 |
| IL−2 concentrations (mean ±SD, pg/mL) | 112.4 ± 28.5 | 108.7 ± 23.3 | 1.604 | 0.208 |
| IL−1α concentrations (mean ±SD, pg/mL) | 69.7 ± 14.7 | 66.1 ± 13.8 | 1.452 | 0.137 |
Abbreviation: CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4; IMA, ischemia‐modified albumin; IL‐1α, interleukin‐1 alpha; IL‐2, interleukin‐2; MIP, macrophage inflammatory protein; HCY, homocysteine; Lp‐PLA2, lipoprotein‐associated phospholipase A2; GFAP, glial fibrillary acidic protein.